Trimetrexate
Back to searchMolecule Structure
Scientific Name
Trimetrexate
Description of the Drug
Trimetrexate is a folate antagonist used for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients as an alternative therapy in combination with leucovorin.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01157
http://www.drugbank.ca/drugs/DB01157
Brand Name(s)
Not Available
Company Owner(s)
Medimmune Oncology Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Dihydrofolate reductase | SINGLE PROTEIN | INHIBITOR | CHEMBL1926 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL3983 | |
| PharmGKB | PA451790 | |
| Human Metabolome Database | HMDB0015288 | |
| DrugBank | DB01157 | |
| PubChem: Thomson Pharma | 14803927 | |
| PubChem | 5583 | |
| Nikkaji | J22.060D | |
| BindingDB | 18268 | |
| EPA CompTox Dashboard | DTXSID3023714 | |
| DrugCentral | 2757 | |
| ChemicalBook | CB1875661 | CB31075279 |
| Guide to Pharmacology | 7613 | |
| rxnorm | TRIMETREXATE | TRIMETREXATE GLUCURONATE |
| PubChem: Drugs of the Future | 12012739 | |
| KEGG Ligand | C11154 | |
| ZINC | ZINC000000598852 |
